In an intensive and constructive dialog between representatives of the Bavarian State Government and the pharmaceutical industry, the “Bavarian Pharmagipfel conference" has identified important questions and challenges in empowering the pharmaceutical sector in Bavaria and ensuring lasting supply of patients with drugs.
After a year of hard work in three different working groups, the results of the Bavarian Pharmagipfel were presented at the end of 2015 by Bavarian Health Minister Huml and Bavarian Minister of Economic Affairs Aigner, assisted by representatives of the pharmaceutical industry. BioM has been very busy in working group III, representing researching biotechnological companies in the field of developing therapeutics, because it was concerned with improving collaborations for running clinical studies at Bavarian medical centers, among other things.
Research and Development in Bavaria
The Pharmagipfel conference (and other subject fields) have agreed to further improve the R&D framework conditions. Minister of Economic Affairs Aigner said, "The pharmaceutical industry in Bavaria is a dynamic economic factor and an important employer. We need a good R&D environment so that our industry will remain innovative. "
A number of proposals for initiatives and activities has been developed in a detailed dialog.
BioM is appointed with setting up a meeting point in the core topic of "Clinical Research and Cooperation" that promotes future exchange between the parties. For this purpose, a "round table" has been created that meets twice a year. Representatives of the clinics and the pharmaceutical industry have been named. For further information, please contact Dr Georg Kääb at BioM.
Corporate Communications, Managing Director Bavarian Biotech Cluster
Joint Declaration of the "Bavarian Pharmagipfel conference" of November 11, 2015 (pdf)